Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7182054 | 0.84 | P2RX4 (0.33) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL28782453 | 0.71 | NPC1 (0.42) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL3017720 | 0.71 | — | — | |
| SCHEMBL11708478 | 0.71 | — | — | |
| SCHEMBL27462081 | 0.70 | CA12 (0.41) | LMNAALDH1A1 | |
| SCHEMBL4753850 | 0.69 | TSHR (0.50) | MAPK1LMNATSHRSCN4ASCN5A | |
| SCHEMBL28896768 | 0.67 | MAOA (0.35) | — | |
| SCHEMBL25197006 | 0.67 | — | — | |
| SCHEMBL31499308 | 0.66 | MTNR1A (0.42) | MAPK1BCHEGAANOX1 | |
| SCHEMBL9661765 | 0.64 | SCN2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1688315-A | Use of selective COX-2 inhibitors for the treatment of urinary incontinence | RECORDATI S P A (CH) | 2005-10-26 | — | — | CN | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-3921623-A1 | METHOD OF TESTING CRYSTALLINITY IN AMORPHOUS PHARMACEUTICAL COMPOSITIONS | ColVisTec AG (DE) | 2021-12-15 | — | — | EP | disclosed |
| CN-113424045-A | Method for testing crystallinity in amorphous pharmaceutical compositions | 科尔维斯科技股份公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020160980-A1 | METHOD OF TESTING CRYSTALLINITY IN AMORPHOUS PHARMACEUTICAL COMPOSITIONS | COLVISTEC AG (DE) | 2020-08-13 | — | — | WO | disclosed |
| CN-109369639-A | A kind of purification process of piroxicam | 重庆三圣实业股份有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-102307857-A | High penetration compositions and their use | CHONGXI YU | 2012-01-04 | — | — | CN | disclosed |
| CN-102264349-A | Sphingolipid activator protein C and related protein and peptide fusogenic properties for transmembrane drug delivery systems | — | 2011-11-30 | — | — | CN | disclosed |
| CN-1233323-C | Orally disintegrating tablet of meloxicam and its preparation | CHENGDU SHENGNUO SCIENCE AND T (CN) | 2005-12-28 | — | — | CN | disclosed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| CN-1546033-A | Orally disintegrating tablet of meloxicam and its preparation | 成都圣诺科技发展有限公司 | 2004-11-17 | — | — | CN | disclosed |
| WO-2000071528-A1 | 4H-1,4-BENZOTHIAZINE-2-CARBOXAMIDES AND THEIR USE AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0938477-A4 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0938477-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998021186-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| CN-1007893-B | Process for preparation of ether matrix of anti-inflammatory oxacikam | PFIZER (US) | 1990-05-09 | — | — | CN | disclosed |
| CN-85102030-A | The preparation method of the ethers parent medicine of antiphlogiston Xi Kamu | — | 1987-01-31 | — | — | CN | disclosed |
| CN-86103603-A | The preparation method of the derivative of benzothiazine dioxide | — | 1987-01-21 | — | — | CN | disclosed |
| CN-86103603-A | The preparation method of the derivative of benzothiazine dioxide | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0034270-A1 | Combinations of agents which give enhanced anti-inflammatory activity | AMERICAN CYANAMID COMPANY (US) | 1981-08-26 | — | — | EP | disclosed |